- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Bioventus-Finanzchef Mark Leonard verkauft Aktien im Wert von 53.639 US-Dollar | 1 | Investing.com Deutsch | ||
| 18.03. | Canaccord Genuity Group Reiterates Buy Rating for Bioventus (NYSE:BVS) | 1 | MarketBeat | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 11.03. | Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million | 1 | Benzinga.com | ||
| 11.03. | Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday | 34 | Benzinga.com | ||
| 11.03. | Bioventus Q4 Results Beat Market; Sees FY25 Earnings, Sales Above Street; Stock Climbs In Pre-market | 1 | RTTNews | ||
| 11.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.03. | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | 109 | GlobeNewswire (Europe) | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen | |
| 11.03. | Bioventus Non-GAAP EPS of $0.15 beats by $0.07, revenue of $153.64M beats by $8.48M | 1 | Seeking Alpha | ||
| 28.02. | Bioventus, Inc.: Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 | 2 | GlobeNewswire (USA) | ||
| 06.01. | Bioventus (NYSE:BVS) Trading Down 5.9% - Here's Why | 1 | MarketBeat | ||
| 03.01. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.01. | Bioventus divests Advanced Rehabilitation business to PE firm | 1 | MassDevice | ||
| 02.01. | Bioventus, Inc.: Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners | 233 | GlobeNewswire (Europe) | DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced today that it has successfully... ► Artikel lesen | |
| 26.12.24 | Bioventus SVP Katrina Church verkauft Aktien im Wert von 26.693 US-Dollar | 2 | Investing.com Deutsch | ||
| 06.11.24 | Earnings call: Bioventus reports robust Q3 growth, raises full-year guidance | 1 | Investing.com | ||
| 06.11.24 | Telefonkonferenz zu Quartalszahlen: Bioventus meldet robustes Wachstum im dritten Quartal und erhöht Prognose für das Gesamtjahr | 1 | Investing.com Deutsch | ||
| 05.11.24 | Bioventus, Inc.: Bioventus Reports Third Quarter Financial Results | 175 | GlobeNewswire (Europe) | Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared... ► Artikel lesen | |
| 05.11.24 | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 69,49 | +0,30 % | Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today | ||
| ORGANOVO | 2,140 | 0,00 % | Organovo, Inc.: Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements | SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,202 | -6,62 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| EXELIXIS | 33,490 | +0,66 % | EXELIXIS, INC. - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 10,920 | -0,18 % | Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians | ||
| TELIX PHARMACEUTICALS | 14,200 | -0,77 % | Telix Pharmaceuticals Limited: Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma | MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase... ► Artikel lesen | |
| MOLECULAR PARTNERS | 3,445 | +0,29 % | Molecular Partners to hold three poster presentations at AACR 2025 | Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer
First... ► Artikel lesen | |
| DENALI THERAPEUTICS | 11,555 | -0,43 % | Denali Therapeutics Aktie: Schatten über dem Weg? | Die Aktie von Denali Therapeutics notiert aktuell bei 11,47 Euro und verzeichnet damit einen Tagesgewinn von 2,05 Prozent. Trotz der leichten Erholung befindet sich das Papier des biopharmazeutischen... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
| CHIMERIX | 7,700 | -1,53 % | Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest | ||
| NEOVACS | 0,035 | -0,85 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 20.01.2025 | Das Instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY wird cum Kapitalmassnahme gehandelt am 20.01.2025 und ex Kapitalmassnahme am 21.01.2025 The instrument BRA AU000000BVS9 BRAVURA SOLUTIONS EQUITY... ► Artikel lesen | |
| ARDELYX | 4,310 | +0,37 % | Ardelyx, Inc.: Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) at the National Kidney Foundation Spring Clinical Meetings | ||
| CODEXIS | 2,358 | +13,26 % | CODEXIS, INC. - 8-K, Current Report | ||
| CORCEPT THERAPEUTICS | 72,44 | +0,58 % | Corcept Therapeutics Incorporated: Primärer Endpunkt der zulassungsrelevanten Phase-3-ROSELLA-Studie von Corcept zu Relacorilant bei Patientinnen mit platinresistentem Eierstockkrebs erreicht | Relacorilant plus nab-Paclitaxel verbessert das progressionsfreie und das Gesamtüberleben ohne verstärkte Nebenwirkungen Ergebnisse unterstützen Marktzulassungsanträge in den USA (NDA)... ► Artikel lesen | |
| SAGE THERAPEUTICS | 6,760 | +1,05 % | Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024.
"We... ► Artikel lesen |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,79 % bei einem Aktienkurs von 9,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.
